Olesoxime is an oral drug whose purpose is to reduce effects of oxidative stress on motor neurons. It was developed by a French patient organisation AFM in partnership with a French company Trophos. It was tested in type 2 and 3 SMA patients during 2011–2014, also in the UK, and the drug appeared to have promising effects. Many of those who were taking it reported increased muscle function and overall stabilisation of their condition.
The olesoxime programme was bought by Roche in 2015 with the purpose of commercialisation. The drug remains in Roche development since then.
Since early 2017, those who participated in the original Trophos trial, including a number of patients from the UK, have been receiving olesoxime under OLEOS clinical trial. However, as of September 2017, no recruitment of new patients is taking place.